MaxCyte, Inc. (MXCT): Revenue

Annual figures by period end, from SEC filings.

$33.03M
Year ended 2025-12-31
$31.05M
Trailing 12 months to 2026-06-30
-9.3%
3-year compound annual growth
+4.8%
5-year compound annual growth
$44.26M2019-12-31: $21.62M2020-12-31: $26.17M2021-12-31: $33.89M2022-12-31: $44.26M2023-12-31: $41.29M2024-12-31: $38.63M2025-12-31: $33.03M$33.03M
2019-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$33.03M-14.5%2026-03-25, From 2025-01-01
2024-12-31$38.63M-6.4%2026-03-25, From 2024-01-01
2023-12-31$41.29M-6.7%2025-03-11, From 2023-01-01
2022-12-31$44.26M+30.6%2024-03-12, From 2022-01-01
2021-12-31$33.89M+29.5%2023-03-15, From 2021-01-01
2020-12-31$26.17M+21.0%2022-03-22, From 2020-01-01
2019-12-31$21.62Mn/a2022-03-22, From 2019-01-01

Revenue at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
MaxCyte, Inc. (MXCT)2025-12-31$33.03M-14.5%
OmniAb, Inc. (OABI)2025-12-31$18.67M-29.3%
Foxo Technologies Inc. (FOXO)2025-12-31$16.37M+304.0%
NRC Health (NRC)2025-12-31$137.39M-4.0%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$6.16M-34.2%
Absci Corp (ABSI)2025-12-31$2.80M-38.2%
iSpecimen Inc. (ISPC)2025-12-31$1.93M-79.2%
OneMedNet Corp (ONMD)2025-12-31$1.36M+111.4%
Medpace Holdings, Inc. (MEDP)2025-12-31$2.53B+20.0%

Compare MXCT, OABI, FOXO, NRC side by side · Screen every company in Services-Commercial Physical & Biological Research ↗